Pulmonalarterielle Hypertonie bei Frauen

Zusammenfassung

Die pulmonalarterielle Hypertonie (PAH) ist eine seltene Erkrankung mit vielen Untergruppen. Frauen sind wesentlich häufiger betroffen bei der „klassischen“ idiopathischen Form, der hereditären und bei der Kollagenose-assoziierten PAH. Es wird vermutet, dass der höhere Östrogenspiegel bei Frauen die Pathophysiologie mit Einengung der kleinen Pulmonalarteriolen als Ursache der PAH zumindest bei den Mutationsträgerinnen begünstigt. PAH-Patientinnen haben ähnliche Symptome wie betroffene Männer, sprechen aber möglicherweise anders auf gezielte PAH-Therapien an. Sie haben im Mittel ein längeres Überleben im Vergleich zu männlichen Patienten. In dieser Arbeit werden wir

Abstract

Pulmonary arterial hypertension (PAH) is a rare disease with several subgroups. Women are more often affected by the “classic” idiopathic form, the heritable form and connective tissue disease associated PAH. It is suspected that the higher estrogen level in women, at least in those who have a predisposing mutation, could increase the remodeling of the small pulmonary arteries. Female PAH patients have similar symptoms as male patients. They may, however, respond better to targeted PAH therapies. On average, female PAH patients show a better survival than male patients. In this work we will

Schlüsselwörter

Frauen - Östrogen - Therapie - pulmonalarterielle Hypertonie

Keywords

pulmonary arterial hypertension - estrogen - therapy - women

• Literatur

• 1 Hoeper MM, Humbert M, Souza R. et al. A global view of pulmonary hypertension. Lancet Respir Med 2016; 4: 306-322
• 2 Vonk Noordegraaf A, Westerhof BE, Westerhof N. The Relationship Between the Right Ventricle and its Load in Pulmonary Hypertension. J Am Coll Cardiol 2017; 69: 236-243
• 3 Hoeper MM, Pausch C, Grunig E. et al. Idiopathic pulmonary arterial hypertension phenotypes determined by cluster analysis from the COMPERA registry. J Heart Lung Transplant 2020; 39: 1435-1444
• 4 Marra AM, Benjamin N, Eichstaedt C. et al. Gender-related differences in pulmonary arterial hypertension targeted drugs administration. Pharmacol Res 2016; 114: 103-109
• 5 Sztrymf B, Coulet F, Girerd B. et al. Clinical outcomes of pulmonary arterial hypertension in carriers of BMPR2 mutation. Am J Respir Crit Care Med 2008; 177: 1377-1383
• 6 Chung L, Liu J, Parsons L. et al. Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype. Chest 2010; 138: 1383-1394
• 7 Hester J, Ventetuolo C, Lahm T. Sex, Gender, and Sex Hormones in Pulmonary Hypertension and Right Ventricular Failure. Compr Physiol 2019; 10: 125-170
• 8 Larkin EK, Newman JH, Austin ED. et al. Longitudinal analysis casts doubt on the presence of genetic anticipation in heritable pulmonary arterial hypertension. Am J Respir Crit Care Med 2012; 186: 892-896
• 9 Hoeper MM, Huscher D, Ghofrani HA. et al. Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: results from the COMPERA registry. Int J Cardiol 2013; 168: 871-880
• 10 Shapiro S, Traiger GL, Turner M. et al. Sex differences in the diagnosis, treatment, and outcome of patients with pulmonary arterial hypertension enrolled in the registry to evaluate early and long-term pulmonary arterial hypertension disease management. Chest 2012; 141: 363-373
• 11 Kjellstrom B, Nisell M, Kylhammar D. et al. Sex-specific differences and survival in patients with idiopathic pulmonary arterial hypertension 2008–2016. ERJ Open Res 2019; 5: 00075-2019
• 12 Song J, Hinderhofer K, Kaufmann LT. et al. BMPR2 Promoter Variants Effect Gene Expression in Pulmonary Arterial Hypertension Patients. Genes (Basel) 2020; 11: E1168
• 13 Eichstaedt CA, Benjamin N, Grünig E. Genetics of pulmonary hypertension and high altitude pulmonary edema. J Appl Physiol 2020; 128: 1432-1438
• 14 Eichstaedt CA, Song J, Benjamin N. et al. EIF2AK4 mutation as “second hit” in hereditary pulmonary arterial hypertension. Respir Res 2016; 17: 141
• 15 Lahm T, Albrecht M, Fisher AJ. et al. 17beta-Estradiol attenuates hypoxic pulmonary hypertension via estrogen receptor-mediated effects. Am J Respir Crit Care Med 2012; 185: 965-980
• 16 Fessel JP, Chen X, Frump A. et al. Interaction between bone morphogenetic protein receptor type 2 and estrogenic compounds in pulmonary arterial hypertension. Pulm Circ 2013; 3: 564-577
• 17 Weiss BM, Zemp L, Seifert B. et al. Outcome of pulmonary vascular disease in pregnancy: a systematic overview from 1978 through 1996. J Am Coll Cardiol 1998; 31: 1650-1657
• 18 Bostock S, Sheares K, Cannon J. et al. The potential effects of pregnancy in a patient with idiopathic pulmonary arterial hypertension responding to calcium channel blockade. Eur Respir J 2017; 50: 1701141
• 19 Gabler NB, French B, Strom BL. et al. Race and sex differences in response to endothelin receptor antagonists for pulmonary arterial hypertension. Chest 2012; 141: 20-26
• 20 Mathai SC, Hassoun PM, Puhan MA. et al. Sex differences in response to tadalafil in pulmonary arterial hypertension. Chest 2015; 147: 188-197